abstract |
A compound for use in a method of treatment of cancer, including precancerous lesions, and adverse events caused by the disease or anti-cancer agents and treatments, such as cancer cachexia, lymphopenia, neutropenia, febrile neutropenia includes in combination an immunomodulatory and at least one anti-cancer agent or treatment suitable for treating the disease. The immunomodulator is a proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride. The anti-cancer agent or treatment suitable for treating the disease provides synergistic effects without additional toxicity when used with the immunomodulatory. The anti-cancer treatment is selected from the following group: surgical procedures, transplantation of bone marrow cells, systemic and localized radiotherapy, and combinations thereof. |